Does HRT Help Osteoporosis? What It Can — and Can’t — Do for Your Bones
Does HRT help osteoporosis? Yes — and the honest answer is more useful than a simple yes. Systemic hormone therapy — estrogen that travels through your whole body, as a pill, patch, gel, or spray — can slow bone loss, raise bone density, and lower fracture risk while you take it. Estrogen is FDA-approved to prevent postmenopausal osteoporosis, though the exact indication is product-specific, so it’s on some labels and not others. What it’s notis a way to undo bone damage that’s already happened — and it’s not a substitute for a bone drug if your fracture risk is already high.
For most healthy women with symptoms, the benefit-and-risk balance is more favorable when you start before age 60 or within 10 years of menopause. That’s a benefit-risk window — not a sign the bone effect switches off the day after.
So the real question isn’t does HRT help osteoporosis. It’s quieter and more worried than that: is it enough for the situation I’m already in — and have I left it too late?That’s what the rest of this page answers, and it’s exactly where most of the internet leaves you hanging.
HRT is most worth discussing for your bones when:
- ✓You’re under 60, or within 10 years of your last period.
- ✓You also have menopause symptoms — hot flashes, night sweats, broken sleep.
- ✓You went through menopause early, or had your ovaries removed young.
- ✓You don’t have a major reason you can’t take estrogen.
- ✓Your fracture risk isn’t already very high.
Don’t assume HRT alone is enough when:
- ⚠You’ve already broken a bone from a minor fall (a “fragility fracture”).
- ⚠You have severe or high-risk osteoporosis.
- ⚠You want to start after 60 only to protect bone, with no symptoms.
- ⚠The only estrogen you take is low-dose vaginal estrogen.
- ⚠You’re on a bone drug like denosumab that needs careful planning to stop.
Jump to: Where do you fit? (8 situations) ↓
The HRT Index is the independent menopause HRT decision layer for women.
By The HRT Index Editorial Team. Educational research — not medical advice, and not medically reviewed by a clinician. This page does not diagnose osteoporosis or decide whether HRT is safe for you. Published June 2026 · Last verified June 2026.
Does HRT help osteoporosis? Four things it does, and one it doesn’t
Systemic HRT has four real effects on bone: it can prevent future loss, preserve the density you already have, modestly increase density, and reduce fractures. The fifth row is the limit — it does not “reverse” osteoporosis by erasing past damage or wiping out fracture risk.People blur these five things together, and that’s where the confusion starts.
Here’s the clearest way we’ve found to keep them straight:
| What you might mean by “help” | Does HRT do it? | The plain truth |
|---|---|---|
| Prevent future bone loss | Yes | Estrogen slows the fast bone loss that comes with menopause. This is an FDA-approved use for some systemic products — check the specific product label. |
| Preserve the bone you have | Yes | It holds onto bone density at the spine and hip while you take it. |
| Build more bone density | Yes, a little | Bone density goes up modestly — real gains, not just “slowed loss.” |
| Reduce fractures (the thing that matters) | Yes | The outcome you actually care about: fewer broken hips and spines. |
| Reverse osteoporosis (rebuild a fragile skeleton) | No, not dramatically | It doesn’t rebuild bone the way bone-building drugs do. “Reverse” oversells it. |
If you remember one thing, remember this: a better bone-density score is nice, but not breaking a bone is the goal.HRT is good at that goal — for the right woman, at the right time. Keep going, because “the right woman at the right time” is doing a lot of work in that sentence.
What we actually verified for this page
This guide is built on current FDA materials, U.S. menopause and bone guidelines, and the original clinical trials — not provider marketing. We separate what the sources directly say from where our own editorial judgment begins, and we date our checks.Here’s exactly what we confirmed.
What we actually verified
- FDA labeling: Estrogen is approved to prevent postmenopausal osteoporosis, with the indication varying by product — and it is not approved to treat osteoporosis you already have.
- The FDA’s 2025–2026 warning changes, including what was removed and what stayed.
- The Menopause Society’s position that hormone therapy prevents bone loss and reduces fractures, rated as their strongest level of evidence.
- The Endocrine Society’s treatment order: bone drugs first for most high-risk women, HRT for a narrower group.
- The U.S. Preventive Services Task Force position on using hormones purely to prevent disease — and the exception inside it.
- The Women’s Health Initiative fracture and bone-density numbers, including the exact medication and the women studied.
- The difference between systemic estrogen and low-dose vaginal estrogen for bone.
How: we read the current primary sources and recorded the date of each. What we did not do: run a trial, review your records, or test a medication ourselves.
We review providers using The HRT Index Verification Standard — our documented process of reading every published price, separating FDA-approved from compounded products, checking state availability and insurance, and re-checking on a fixed schedule. It rests on five pillars, always in this order: clinical legitimacy, care quality, medication fit, price transparency, and access. We never turn it into a fake numeric score.
One thing the headlines oversimplified
You may have seen that “the FDA removed the black box warning from HRT.” The details matter. On November 10, 2025, the FDA requested labeling changes to remove specific statements about heart disease, breast cancer, and probable dementia from the strongest warning (the “boxed warning”) on menopausal hormone products. On February 12, 2026, the FDA approved updated labels for the first six products — Bijuva, Divigel, Cenestin, Enjuvia, Estring, and Prometrium. The warning about uterine (endometrial) cancer stayed on estrogen-only systemic products. So this is a real, ongoing shift — not a blanket “HRT is now warning-free” moment, and the current label for your exact product still controls. (FDA, Feb 12 2026)
How estrogen protects bone, in plain English
Your bones are alive. They’re constantly broken down and rebuilt. Estrogen keeps the “breakdown” crew in check. When estrogen drops at menopause, breakdown outpaces rebuilding, and bone is lost fast. Replacing estrogen slows that breakdown — which is why systemic HRT protects bone.
Think of bone like a bank account with constant deposits and withdrawals. Before menopause, estrogen keeps withdrawals slow. After menopause, the brakes come off. The cells that dissolve old bone (called osteoclasts) get more active, and bone loss speeds up sharply — by some estimates, women can lose up to 20% of their bone density across the menopause transition and the early years after it. (Endocrine Society) If you went through menopause early, that’s even more years of fast loss.
Systemic estrogen puts the brakes back on. It slows the breakdown, helps protect the inner scaffolding of bone, and nudges your bone-density score back up. Here’s a detail that gets lost: estrogen has randomized fracture-reduction evidence in generally healthy postmenopausal women — women who weren’t picked because they already had osteoporosis. (NIH/PMC) That’s part of why it works so well as a prevention tool, early, before things get bad.
A quick vocabulary note: Doctors increasingly say MHT (menopausal hormone therapy) instead of HRT(hormone replacement therapy). Same thing. We use HRT here because that’s what most people type — but if your clinician says MHT, they mean the same treatment.
The eight-situation decision matrix: where do you fit?
HRT’s value for your bones isn’t one answer — it’s eight, because your situation changes everything. The strongest case is a woman close to menopause who also has symptoms. The weakest case is starting it after 60 just for bone, or relying on vaginal estrogen. Find your row below.This is the part of the page we’d most want a friend to see.
We built this by lining up FDA labeling, The Menopause Society, the Endocrine Society, and the U.S. Preventive Services Task Force side by side — the work you’d otherwise do across a dozen tabs.
| Your situation | What systemic HRT may do | Is it usually enough as the whole bone plan? | Smarter starting point |
|---|---|---|---|
| Early menopause, ovaries removed young, or primary ovarian insufficiency (ovaries stop early) | Replaces estrogen during years your body shouldn’t be without it; helps protect bone through that window | Can be central — but a past fracture or very low density still matters | A menopause clinician; add in-person bone care if you’ve fractured or have very low density |
| Under 60 or within 10 years of menopause, with symptoms, no major risk flags | Treats symptoms and lowers bone loss and fracture risk at once | Often yes, for prevention — if your fracture risk isn’t already high | Menopause-focused care plus an appropriate bone scan |
| Osteopenia (low bone mass), no prior fracture | May hold or improve density and slow further loss | Sometimes — but “osteopenia” alone doesn’t tell you your true fracture risk | Look at your full picture (T-score, age, family history, FRAX), not the score alone |
| Established osteoporosis or high fracture risk | May still treat symptoms, but it’s not FDA-approved to treat osteoporosis and isn’t the default first choice for fractures | Usually not alone — guidelines put bone drugs first here | A clinician who can manage both fracture risk and menopause |
| Prior hip or spine fracture, or several fragility fractures | May be part of the plan if it’s right for your symptoms | No — not as the assumed sole treatment | In-person bone evaluation first; very high risk may need bone-building medicine |
| Thinking about starting after 60 / more than 10 years past menopause | Benefit isn’t zero, but starting late is a different calculation than continuing | Don’t assume it’s the preferred bone-only treatment | Individual, ideally in-person review of heart, clot, breast, and fracture risk |
| Using low-dose vaginal estrogen for dryness or urinary symptoms | Treats local tissue; very little reaches your bloodstream | No — it’s not a bone treatment | Keep the “dryness” question and the “bone” question separate |
| Planning to stop systemic HRT | Bone protection may fade after you stop | A follow-up plan may be needed if your risk is still high | Re-check density and fracture risk before stopping — don’t leave a gap |
Source basis: row logic draws on FDA product labeling, The Menopause Society 2022 Position Statement, the Endocrine Society osteoporosis guideline, and the USPSTF. Every “smarter starting point” is our editorial routing — a judgment call from the verified facts — not a quote from any guideline or a treatment recommendation for you personally.
Found your row? The next step isn’t a leap — it’s just getting organized before you spend money on a consult.
→ Find your situation, get your starting point. Find My HRT Path asks about your symptoms, where you are in menopause, your safety history, and what you prefer — then points you to a starting place and flags when your answers mean a do-it-yourself online subscription isn’t the right first move. No diagnosis, no pressure.
Not sure which row is yours? Find My HRT Path routes your situation in 60 seconds — including when in-person care should come first.
Find My HRT Path →Free · 60 seconds · No diagnosis
How much does HRT actually help? The real numbers
In the 16,608-woman Women’s Health Initiative trial, women on hormone therapy had fewer fractures than women on a placebo — and their hip bone density rose while the placebo group’s stayed flat. The effect is real and measurable. But the size depends on the exact medication and the exact women studied, so treat these as evidence, not a personal guarantee.
Vague claims don’t help you decide. Here’s the hard data, in one place:
| Study | Who & what | What happened to bone | The catch (and source) |
|---|---|---|---|
| Women’s Health Initiative, estrogen + progestin arm | 16,608 women, ages 50–79, with a uterus; oral conjugated equine estrogen 0.625 mg + medroxyprogesterone acetate 2.5 mg daily vs. placebo, ~5.6 years | 8.6% of the hormone group had a fracture vs. 11.1% on placebo — a relative drop of about 24% in total fractures and roughly 34% in hip fractures. Total hip bone density rose 3.7% vs. 0.14% at 3 years | Participants were enrolled without regard to bone density or fracture risk — this was not a trial in women with established osteoporosis. (Cauley/WHI, JAMA 2003) |
| The Menopause Society, 2022 position | Healthy postmenopausal women | Rates “prevents bone loss” and “reduces fracture risk” as Level I — their strongest evidence grade | A general statement, not a personal prescription. (Menopause Society) |
| Head-to-head trial (281 women after hip fracture) | Estradiol gel + progesterone vs. risedronate (a common bone drug), 4 years | No statistically significant difference in repeat fractures between the two; total hip bone density rose 2.8% on hormones vs. essentially unchanged on the bone drug | Small, and not designed to prove the two are equivalent. (Park et al., 2021) |
A word on what those percentages mean, because honesty builds trust. In that landmark trial, the gap between 8.6% and 11.1% works out to about 2.5 fewer women per 100 having a fracture over a mean 5.6 years. That’s meaningful at the population level — but it can’t tell you whether you’llfracture. And the trial’s bone benefit came packaged with its other risks, which is exactly why this isn’t a one-size decision.
One more caution we won’t skip: that trial used oral conjugated estrogen plus a synthetic progestin. A modern estradiol patch is not automatically the same evidence — and a compoundedhormone preparation (custom-mixed at a pharmacy) is definitely not. We’ll come back to compounded products, because that’s where a lot of women get misled.
Can HRT reverse osteoporosis — or just prevent more loss?
HRT can raise your bone-density score and lower fracture risk, but “reverse osteoporosis” is usually too strong a word. A better score doesn’t erase a past fracture, remove all future risk, or prove HRT alone is the right long-term plan. Think “stop the slide and strengthen,” not “rebuild from scratch.”
Bone density is only part of bone strength. A medication can improve the number on your scan without making your bones bulletproof. Here’s the clean way to see it:
| What HRT can improve | What it does not make disappear |
|---|---|
| Bone mineral density (your DXA number) | A prior fragility fracture — your single strongest risk signal |
| Your diagnostic category (a T-score can shift from osteoporosis toward osteopenia) | Underlying causes of bone loss (thyroid, steroids, other conditions) |
| Bone turnover (it slows the breakdown) | Your baseline risk if you stop treatment |
Can a score actually move from the “osteoporosis” range into the “osteopenia” range with treatment? Yes, it can happen. But a label change on a report is not the same as being cured — and we’d be doing you a disservice to imply otherwise.
Our one honest admission — and we’d rather you hear it from us than discover it later:
HRT is not the strongest or simplest answer for every woman who already has osteoporosis. If preventing fractures is your only goal and your risk is high, a dedicated bone medicine is often the better place to start. If that’s you, don’t force HRT — and don’t let anyone sell it to you as a complete fix. Skip to HRT vs. bone drugs, or talk to an in-person bone specialist.
Now the other half of that truth, because this is where HRT earns its place: HRT becomes genuinely compelling when you also have menopause symptoms and you’re still in the early window. Then it can address your hot flashes and night sweats andhelp prevent bone loss at the same time — which no bone drug does. For that woman, HRT isn’t a compromise. The trick is knowing which woman you are, which is exactly what the matrix above is for.
Does HRT help osteopenia?
For osteopenia — low bone mass that hasn’t reached full osteoporosis — systemic HRT can help hold or improve bone density, especially if it’s also treating your menopause symptoms. But osteopenia is a category on a scan, not a complete fracture-risk verdict, so the decision shouldn’t ride on the T-score or the estrogen dose alone.
First, the words, because they get thrown around. After menopause, a bone-density scan gives you a T-score, which compares your bone to a healthy young adult:
- −1.0 or higher: normal
- Between −1.0 and −2.5: osteopenia (low bone mass)
- −2.5 or lower: osteoporosis
So osteopenia sits in the middle. Here’s the catch most pages skip: a fracture history or enough other risk factors can matter even when your T-score is better than −2.5. Two women with the same “osteopenia” label can have very different real-world risk. (Bone Health & Osteoporosis Foundation)
A lot of women land here after reading forums and ask the same thing: “What dose of estrogen should I be on for osteopenia?” We understand the instinct, but we can’t answer it, and neither can a stranger online — and that’s the responsible answer. There is no universal “osteopenia dose.” The right product, route, and dose depend on your symptoms, side effects, whether you have a uterus, your overall risk, and what you’re actually trying to achieve. Please don’t crank up a patch dose to chase a scan number.That’s how people trade one risk for another.
What actually changes the decision is your full picture. Run through this before any consult:
- Your T-score category — and which bone it came from
- Any previous fracture, especially from a minor fall
- The FRAX factors (a widely used 10-year fracture-risk calculator): a parent’s hip fracture, smoking, steroid use, low body weight, rheumatoid arthritis, heavy alcohol use, and your age (USPSTF)
- Whether you also have menopause symptoms (which can tip HRT from “maybe” to “makes sense”)
- Your timing (how long since your last period)
- Any reason you can’t take estrogen
Bring those to a clinician, not to a dosing chart.
Which forms of HRT protect bone — and is a patch better than a pill?
Both oral and through-the-skin (transdermal) systemic estrogen can affect bone. But the FDA bone indication and the trial evidence are product-specific, so “which form is best for bones” doesn’t have one universal answer — and the route is a clinician’s call, not a slogan.
Oral estrogen (pills) and transdermal estrogen (patches, gels, sprays) both slow bone loss and can improve density. The large fracture-reduction evidence — the WHI trial — used oral conjugated equine estrogen, not a modern estradiol patch; but other studies show transdermal estradiol also affects bone markers. Whether one route outperforms the other specifically for bone hasn’t been established definitively.
What isestablished: transdermal estrogen may carry a lower blood-clot risk for some women compared to oral, and that consideration can matter in route selection — but that’s a broader risk calculation, not a bone-specific one. Route and dose are a conversation between you and your prescriber, based on your full picture.
On compounded hormones:
Compounded hormone preparations — custom-mixed at a pharmacy, sometimes marketed as “bioidentical” — are not FDA-approved, and the FDA does not have evidence that they are safer than or as effective as FDA-approved products for bone. Don’t assume a compounded cream or pellet carries the same bone evidence as a studied, approved product. (FDA)
⚠ Critical warning if you take denosumab (Prolia)
Denosumab should not be delayed or stopped without your clinician lining up another bone treatment to take its place. Otherwise bone turnover can rebound, density can drop fast, and fracture risk can spike. (Endocrine Society) Starting HRT on your own is not a substitute for a proper denosumab transition — this is a “coordinate with your clinician” situation, every time.
HRT vs. osteoporosis drugs: which usually comes first?
For most women with established osteoporosis or high fracture risk, current guidelines put dedicated bone drugs (bisphosphonates first, then others) ahead of HRT as the primary treatment. For a selected group — younger women with menopause symptoms, recently postmenopausal, without high fracture risk — HRT can serve as both a symptom treatment and a bone preventive.
The Endocrine Society’s osteoporosis guideline places bisphosphonates (alendronate, risedronate, zoledronic acid) as the standard first-line pharmacological treatment for postmenopausal women with osteoporosis or high fracture risk. HRT appears as an option for a narrower profile: women who also have menopause symptoms and are in the earlier postmenopausal window. (Endocrine Society)
The reason is practical: bisphosphonates were developed and studied specifically for reducing fractures in women who already have osteoporosis. HRT was studied in generally healthy women without established osteoporosis. The populations are different, and the indications reflect that.
Where HRT has a genuine advantage: bone drugs do nothing for hot flashes, night sweats, or sleep disruption. If those symptoms are significant, HRT can address both problems at once. That dual role is why it earns a place in guidelines — for the right woman.
Can you take both?Yes, in some cases — a bone drug and HRT together is a real clinical option, discussed case by case. That’s a conversation for a prescriber who manages both fracture risk and menopause.
Do you need a DEXA scan? T-score and FRAX explained
A DEXA scan (dual-energy X-ray absorptiometry) is the standard way to measure bone density. Your T-score tells you where your bones sit on the density spectrum. But a T-score alone doesn’t determine your real fracture risk — that’s what FRAX adds.
The FRAX calculator uses your T-score plus clinical risk factors to estimate your 10-year probability of a hip fracture and a major osteoporotic fracture. Those factors include: age, body mass index, a prior fragility fracture, a parent who fractured a hip, current smoking, steroid use (glucocorticoids), rheumatoid arthritis, and high alcohol use. (USPSTF)
Two women can have identical T-scores and completely different FRAX-based fracture risk — because a woman who smokes, had a mother who broke her hip, and has been on steroids has far more than her T-score working against her. That’s why the checklist in the osteopenia section above matters more than the single number on your report.
When is a DEXA scan typically recommended? The USPSTF recommends bone-density screening for:
- Women aged 65 and older
- Younger postmenopausal women whose 10-year fracture risk is equal to or greater than that of a 65-year-old white woman with no additional risk factors (assessed by a tool like FRAX)
If you went through menopause early, had your ovaries removed young, or have multiple FRAX risk factors, discuss earlier screening with your clinician — the standard age thresholds were built for average-risk women.
The question underneath this search
The question underneath nearly every search like this one isn’t really “does HRT work?” It’s quieter and more worried than that: “is HRT enough for the situation I’m already in — or have I left it too late?” If that’s the knot in your stomach, you’re in exactly the right place, and the honest answer is this: it depends on your row in the matrix above, and you almost certainly have notrun out of options. That’s not a brush-off — it’s the whole reason we built the tool.
Your next step, by situation
The right next move depends less on whether HRT “works” in general and more on where you are: your fracture risk, your timing, your symptoms, and your safety history. Here’s the honest routing — including the cases where we’d send you away from online care.
If you have symptoms plus a bone-protection goal, and no major red flags
Talk to a qualified menopause clinician about systemic HRT and ask how bone monitoring fits in.
See whether online HRT care fits your situation →If you have osteopenia and no prior fracture
Gather your full DEXA report and ask for a fracture-risk assessment. Don’t raise an estrogen dose based on the T-score alone.
Start with Find My HRT Path →If you have osteoporosis, a prior hip or spine fracture, or very high risk
Start with an in-person clinician who manages bone disease, and bring the checklist from the DEXA section. HRT can still be discussed, but it shouldn’t replace fracture-focused care.
If you use low-dose vaginal estrogen only
Keep treating the local symptoms with your prescriber, but handle bone screening as a separate question.
Understand vaginal estrogen →If you’re not sure which category you’re in
That’s the most common spot to be, and it’s fine.
Still not sure which HRT program is right for you? Take our free 60-second matching quiz. Find My HRT Path may point you toward online care, an in-person starting point, or more reading. If a recommendation uses an affiliate link, we disclose that relationship before you click. We’d rather earn your trust than your click.
Find My HRT Path →Free · 60 seconds · No diagnosis
Frequently asked questions
Does HRT prevent osteoporosis?
Yes. Systemic menopausal hormone therapy slows postmenopausal bone loss and reduces fractures while you take it. Whether it’s the right prevention choice for you depends on your symptoms, age, timing, route, and medical history. (Menopause Society)
Can HRT treat osteoporosis?
It may be prescribed for menopause symptoms in a woman who also has osteoporosis, but it is not FDA-approved to treat established osteoporosis, and trials haven’t shown fracture reduction in women selected specifically for it. Dedicated bone drugs usually lead for that goal. (Endocrine Society)
Can HRT reverse osteoporosis?
HRT can improve bone density and lower fracture risk, but “reverse” oversells it — a past fracture and your underlying risk don’t simply disappear. A better scan number is not the same as a cure.
Does HRT help osteopenia?
It may hold or improve bone density in selected women, especially when it’s also treating menopause symptoms. Osteopenia alone doesn’t decide between HRT and a bone drug.
Does vaginal estrogen protect bones?
No. Low-dose vaginal estrogen is for local tissue and very little reaches the bloodstream, so it’s not an osteoporosis treatment. Check the specific product, because a few vaginal rings are actually systemic. (Menopause Society)
What’s the best HRT dose for osteoporosis?
There’s no universal online answer. The right dose and route depend on the product, your goal, your symptoms, your risk profile, whether you have a uterus, and side effects — a clinician decides this with you.
Is HRT better than bisphosphonates?
Not as a general rule. Bisphosphonates are commonly first-line for high fracture risk; HRT is a dual-purpose option for selected younger or recently menopausal women with symptoms. (Endocrine Society)
Can I start HRT after 60 for osteoporosis?
Possibly, in selected cases — but a late startneeds a more careful, individual risk review, and it shouldn’t be treated as a routine bone-only solution.
Do I need progesterone with estrogen?
If you have a uterus, systemic estrogen is generally paired with a progestogen to protect your uterine lining. After a hysterectomy, estrogen alone may be appropriate. (Bone Health & Osteoporosis Foundation)
How long does HRT take to improve bone density?
Bone-density change is measured over time, not in weeks. The Endocrine Society suggests rechecking bone density about every one to three years in treated women at high fracture risk — and that interval is a monitoring schedule, not a promise of when your own result will move. (Endocrine Society)
What happens to bone after stopping HRT?
Bone density starts dropping again, and some women need another medicine to keep protection going. Re-check your fracture risk and plan the transition before stopping.
Is compounded HRT proven to work like FDA-approved HRT for bone?
Don’t assume so. Compounded hormones aren’t FDA-approved, and the FDA says it doesn’t have evidence they’re safer or more effective than approved hormone therapy. (FDA)
Did the FDA remove the warnings from HRT?
Partly, and gradually. The FDA requested removal of the boxed-warning statements about heart disease, breast cancer, and dementia in November 2025, and approved updated labels for the first six products in February 2026. The uterine-cancer warning stayed on estrogen-only systemic products, and other product-specific warnings remain. (FDA)
How this guide was produced
We — The HRT Index Editorial Team — compared current FDA materials, U.S. menopause and osteoporosis guidance, osteoporosis-screening recommendations, and the original randomized trials. We separated direct source statements from our own editorial routing conclusions, and recorded the date of every regulatory and guideline check. We did not examine an individual patient or test any medication ourselves. The HRT Index is the independent menopause HRT decision layer for women.
Why this page exists:women are usually handed two half-answers — “HRT protects bone” and “osteoporosis needs an osteoporosis drug” — with no one explaining which one applies to whom. This page exists to show which is true in which situation, and when both matter.
Educational only — not medical advice. FDA-approved and compounded options are labeled distinctly throughout, and compounded is never implied to be safer than, more natural than, or equivalent to FDA-approved medication. Last verified 2026-06-25.
Sources
- U.S. Food and Drug Administration — Menopause (women’s health topics): approved indications, prevention vs. treatment, compounded “bioidentical” hormones.
- FDA / HHS — FDA Approves Labeling Changes to Menopausal Hormone Therapy Products (Feb 12, 2026) and the November 10, 2025 labeling-change request.
- FDA — Divigel prescribing information (2026), as a product-label example.
- The Menopause Society — 2022 Hormone Therapy Position Statement (bone loss and fracture prevention rated Level I; timing and risk stratification).
- Endocrine Society — Pharmacological Management of Osteoporosis in Postmenopausal Women (bisphosphonates first-line; HRT for a selected profile; denosumab discontinuation; monitoring interval).
- U.S. Preventive Services Task Force — Hormone Therapy for the Primary Prevention of Chronic Conditions (2022) and Osteoporosis Screening.
- Women’s Health Initiative — Cauley JA et al., Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density (JAMA, 2003).
- Park et al. (2021) — randomized comparison of menopausal hormone therapy vs. risedronate after hip fracture.
- Bone Health & Osteoporosis Foundation — bone-density testing and T-score categories.